Epilepsy Financial Planning: AED Costs, SSI Listing 11.02, and Special Needs Trust Strategy

Approximately 3.0 million U.S. adults have active epilepsy, and roughly 1 million children and adolescents are affected — making it one of the most common chronic neurological conditions in the country.¹ For most families, epilepsy financial planning is not a single event but a shifting target: a child whose seizures are fully controlled on one medication may need multiple drug trials over a lifetime, and the roughly 30% of people who develop drug-resistant epilepsy face an entirely different financial profile — recurring specialist visits, expensive newer antiseizure medications, and potentially tens of thousands of dollars in device-implant surgery costs.² This guide covers the financial planning considerations that matter most for epilepsy families: SSI and disability benefits, AED costs, driving restrictions and employment, surgical options for refractory epilepsy, and how to structure Special Needs Trusts and ABLE accounts around a condition that can look very different from one person to the next.

Why epilepsy financial planning is different

Generic disability planning resources treat epilepsy as a single condition with a predictable financial profile. It isn't. The gap between a person whose seizures resolved in childhood on a single generic medication and a person with refractory temporal lobe epilepsy who has failed six drug trials and needs brain surgery is as wide as any two medical diagnoses. Financial planning that doesn't start with the severity profile will miss the most important variables:

• The spectrum determines whether SSI applies at all. A person with fully controlled epilepsy who drives, works full-time, and has no functional limitations does not qualify for SSI. A person with drug-resistant seizures that prevent driving, limit employment, and require frequent hospitalizations almost certainly does. The planning tools — SNT, ABLE, benefits counseling — are only financially meaningful for the latter group.
• AED costs are invisible until a drug changes. Most generic antiseizure medications cost $10–$50/month. But newer agents — lacosamide (Vimpat), brivaracetam (Briviact), and especially cannabidiol (Epidiolex) for Dravet syndrome and Lennox-Gastaut — carry annual list prices of $10,000–$45,000+. A formulary change, insurer switch, or new drug trial can transform the medication budget overnight.
• Driving restrictions create an employment problem that compounds over time. Most states require a seizure-free period of 3–12 months before a person with epilepsy can legally drive.³ For someone who has uncontrolled seizures several times per year, this may mean never holding a driver's license — or spending years in a cycle of losing and regaining driving privileges. The financial impact of permanently relying on rideshare, public transit, or family for transportation is substantial and almost never priced into early financial plans.
• Refractory epilepsy generates surgical costs that require advance planning. Temporal lobectomy, vagus nerve stimulator implantation, and responsive neurostimulation (RNS) devices each generate total hospital costs of $30,000–$100,000+. Even with Medicaid coverage, out-of-pocket exposure, out-of-network specialists, and travel for centers of excellence create real financial gaps.

The epilepsy spectrum and its financial planning implications

Not every person with epilepsy needs a Special Needs Trust. Understanding where a person falls on the spectrum determines which planning tools are appropriate:

SSI and disability benefits: SSA Listing 11.02 explained

The Social Security Administration evaluates epilepsy under Listing 11.02 (Epilepsy) in the adult Blue Book and the parallel 111.02 for children. A person whose epilepsy meets one of the Listing 11.02 criteria is presumed disabled without further assessment of work capacity. The 2026 criteria have four pathways:⁴

• 11.02A — Generalized tonic-clonic (GTC) seizures: occurring at least once per month for at least 3 consecutive months despite adherence to prescribed treatment.
• 11.02B — Dyscognitive (focal aware/aware impaired) seizures: occurring at least once per week for at least 3 consecutive months despite adherence to prescribed treatment.
• 11.02C — GTC seizures at lower frequency plus marked limitation: occurring at least once every 2 months for at least 4 consecutive months, AND a marked limitation in physical functioning, understanding/remembering/applying information, interacting with others, concentrating, or managing oneself.
• 11.02D — Dyscognitive seizures at lower frequency plus marked limitation: occurring at least once every 2 weeks for at least 3 consecutive months, AND a marked limitation in one of the same functional areas as 11.02C.

Two important counting rules: (1) Multiple seizures in a single 24-hour period count as one seizure. (2) The qualifying period cannot begin until at least one month after treatment was started — meaning SSA expects the medication to have been given adequate time to work before the qualifying count begins.

For people who do not meet a Listing threshold but whose epilepsy still severely limits work capacity, SSA also conducts a residual functional capacity (RFC) assessment. A person who cannot drive, cannot work at heights or near moving machinery, cannot operate commercial vehicles, and has medication side effects that impair concentration may still be found disabled even if seizure frequency doesn't meet 11.02. The RFC pathway is less predictable than meeting a Listing; a disability attorney or benefits counselor is essential for these cases.

SSI resource and income limits

SSI for 2026 pays up to $994/month (the Federal Benefit Rate) and requires the beneficiary to have no more than $2,000 in countable resources. Assets in a properly-structured third-party Special Needs Trust do not count toward the $2,000 limit. An ABLE account balance up to $100,000 also does not count. If an SSI beneficiary receives a direct inheritance or personal injury settlement that pushes countable resources above $2,000, SSI and Medicaid are suspended until resources are spent down — which is why beneficiary designations and SNT planning matter even when the person is receiving SSI today.

Driving restrictions and the employment problem

Every state requires a seizure-free period before a person with epilepsy can drive. The minimum period varies: 3 months in the most permissive states, 12 months in five states plus the District of Columbia, with 6 months being most common for adults.³ Commercial driver's licenses (CDL) require federal medical certification — current federal regulations prohibit commercial driving for anyone with a seizure disorder unless they qualify for an individual exemption, which is a formal DOT process with strict criteria.

The financial planning implications of permanent or recurring driving restriction are underappreciated:

• Transportation costs are substantial and long-term. A person who cannot drive in a car-dependent metro area may spend $3,000–$8,000/year on rideshare, paratransit, and taxi services for medical appointments, work commuting, and daily needs. Over a 40-year adult life, that's $120,000–$320,000 in 2026 dollars — before inflation. The SNT should model this explicitly, and the ABLE account can fund transportation as a qualified disability expense.
• Career restrictions eliminate certain industries entirely. Commercial truck driving, school bus driving, many construction trades, forestry, fishing, and certain healthcare roles (operating room duties in some hospitals) have explicit seizure disorder exclusions. A financial plan for a young adult with refractory epilepsy should account for a narrowed career set and, where applicable, SSI work incentive optimization rather than assuming full labor market participation.
• The SSI income formula rewards partial employment. SSI excludes the first $65/month in earned income plus half of everything above that. A person with epilepsy who works part-time at $800/month retains SSI of $994 − $367.50 = $626.50, for a total monthly income of $1,426.50. Working — even part-time within a reduced career set — is almost always financially better than relying solely on SSI. The SEIE exclusion ($9,730/year for SSI beneficiaries under 22 who attend school) and Section 1619(b) Medicaid protection make the transition to part-time work lower-risk than many families assume.

AED costs: generic drugs vs. newer agents

For most people with epilepsy, medication costs are manageable: most of the oldest antiseizure medications (levetiracetam, lamotrigine, valproate, carbamazepine, topiramate, zonisamide) are available as generics and cost $10–$50/month with standard insurance. The financial picture changes dramatically for newer agents and for rare severe epilepsies:

• Lacosamide (Vimpat) and brivaracetam (Briviact): Still under patent or recently generic; monthly costs of $300–$600 without coverage are common at the brand-name list price. Generic lacosamide has become available and significantly reduced costs for some patients, but coverage depends on formulary tier.
• Cannabidiol (Epidiolex) for Dravet syndrome and Lennox-Gastaut syndrome: The FDA-approved cannabidiol formulation carries a list price of approximately $32,500–$45,000/year depending on body weight, with dosing at 10–20 mg/kg/day.⁵ With insurance coverage, out-of-pocket costs are frequently $0–$50/month through patient assistance programs; without coverage, costs are prohibitive. Medicaid coverage varies by state formulary. Families in states with restrictive formularies have had to appeal, change states, or fund medication privately through the SNT — which is an appropriate distribution as a health expense.
• Fenfluramine (Fintepla) for Dravet syndrome: Annual list price in the $55,000–$80,000 range as of recent market data; access restrictions through a REMS program due to cardiac monitoring requirements. Insurance coverage varies.
• Multi-drug regimens for drug-resistant epilepsy: A person with refractory epilepsy managed on three or four agents — including one or two newer drugs — may have annual medication costs of $15,000–$50,000+ at list prices before insurance. The SNT can fund medication costs not covered by insurance or Medicaid as a health expense without affecting SSI.

For families managing expensive AEDs, the ABLE account is the most efficient vehicle for routine medication costs up to $20,000/year (2026 contribution limit). The SNT is appropriate for exceptional or one-time costs above what the ABLE can absorb.

Surgical and device options for refractory epilepsy: costs and financial planning

When two or more adequate antiseizure medication trials have failed and seizures continue, surgical evaluation is appropriate. The financial planning challenge is that surgical options involve significant upfront costs — even with insurance — and may require repeat procedures.

Resective surgery (temporal lobectomy and cortical resection)

Resective surgery — removing the brain tissue where seizures originate — is the most effective treatment for drug-resistant temporal lobe epilepsy. Seizure-freedom rates of 60–70% have been reported for temporal lobe surgeries.⁶ Total hospital charges run $40,000–$100,000+ depending on pre-surgical workup (including ictal SPECT, PET, intracranial EEG monitoring, and neuropsychological testing, each of which may involve separate admissions). Medicaid covers medically necessary epilepsy surgery, but pre-authorization requirements, in-network specialist limitations, and cost-sharing for hospital days can generate out-of-pocket exposure of $1,000–$10,000+ per episode. The SNT is the appropriate backstop.

Vagus nerve stimulator (VNS)

The vagus nerve stimulator — a device implanted under the left clavicle with a lead connecting to the vagus nerve — delivers periodic electrical pulses that reduce seizure frequency in drug-resistant epilepsy. VNS does not eliminate seizures (unlike resective surgery in good candidates) but can reduce frequency by 50% or more in responsive patients. The device requires battery replacement every 3–12 years depending on the model and stimulation settings.

Total implantation costs including device, surgery, and hospital stay run $35,000–$60,000+ based on Medicare reimbursement benchmarks (the new implant procedure Medicare rate increased approximately 48% effective January 2026).⁷ Battery replacement at end-of-service is an additional $20,000–$35,000 procedure. For a person implanted at age 12 who lives to 70, the SNT financial plan should budget $80,000–$150,000 in present-value device replacement costs across the lifespan — separate from the seizure-related hospitalization savings the device may generate.

Responsive neurostimulation (RNS)

The RNS System (NeuroPace) is an implanted device that detects abnormal brain electrical activity and delivers responsive stimulation to abort seizures before they fully develop. Unlike VNS, RNS is an intracranial device placed directly in the skull. It is indicated for drug-resistant focal epilepsy with one or two seizure foci. Total implantation and hospitalization costs are comparable to VNS — $50,000–$80,000+ — with similar device replacement considerations. Ongoing programming visits run $500–$2,000 per visit, typically several per year in the first two years after implantation.

Dietary therapy

The ketogenic diet and its variants (modified Atkins, low glycemic index) are medically supervised dietary treatments for drug-resistant epilepsy, particularly effective in children. Dietitian supervision runs $100–$300/session; specialized foods and supplements add $200–$500/month; hospital initiations add a brief admission cost. SNT can fund dietary therapy as a medical health expense; ABLE accounts can also fund it under the health and wellness QDE category.

Dravet syndrome and Lennox-Gastaut syndrome: the severe childhood epilepsies

Two epilepsy syndromes deserve specific financial planning attention because they involve both severe refractory seizures and significant intellectual/developmental disability — requiring the full spectrum of special needs financial planning tools, not just the epilepsy-specific considerations above.

• Dravet syndrome is caused primarily by SCN1A gene mutations. Seizures typically begin in the first year of life with febrile seizures and progress to multiple seizure types, including prolonged convulsive seizures requiring emergency rescue medication (rectal diazepam, intranasal midazolam). Intellectual disability and behavioral challenges are the rule. Almost all individuals with Dravet syndrome qualify for SSI under Listing 11.02 or under intellectual disability listings. Epidiolex and fenfluramine are FDA-approved specifically for Dravet; total annual drug costs for the dual regimen can exceed $80,000 at list price. Medicaid is the primary payer, but SNT coverage of gaps is essential.
• Lennox-Gastaut syndrome (LGS) is characterized by multiple seizure types (tonic, atonic "drop attacks," absence), intellectual disability, and a distinctive EEG pattern. Drop attacks cause frequent falls and injury — helmet use, padded environments, and supervision costs are real financial items. Epidiolex, clobazam (Onfi), rufinamide (Banzel), and lamotrigine are all used in LGS management. The financial plan for an LGS family looks much like planning for any severe developmental disability: third-party SNT, HCBS waiver enrollment urgently, ABLE account, life insurance funding of SNT corpus, and full beneficiary designation audit.

For both syndromes, SNT sizing depends on care setting and HCBS waiver availability. Without waiver-funded residential or day programming, SNT targets for adults with Dravet or LGS in a community living setting typically range from $750,000–$2,000,000 in today's dollars, depending on the level of behavioral and medical supervision needed. See the Lifetime Care Cost Calculator to model the specific scenario.

ABLE accounts for epilepsy

ABLE accounts (full 2026 guide here) are particularly well-suited to individuals with partially controlled or drug-resistant epilepsy who maintain some independence and employment capacity. Key 2026 parameters:

• Age eligibility expanded to 46 (ABLE Age Adjustment Act, effective January 1, 2026). Epilepsy with onset before age 46 qualifies — and most epilepsy in the U.S. has childhood or young-adult onset, meaning the vast majority of people with epilepsy who meet SSI or SSDI disability criteria now meet the age requirement regardless of current age.
• $20,000/year contribution limit (2026). Parents, grandparents, employers, and the beneficiary can all contribute up to the annual limit. ABLE funds grow tax-free and are withdrawn tax-free for qualified disability expenses.
• ABLE-to-Work: additional $15,650/year for employed beneficiaries who deposit earned income. A working adult with epilepsy can shelter $35,650/year in the ABLE account — none of which counts toward SSI's $2,000 resource limit.
• Qualified disability expenses that are particularly relevant for epilepsy: prescription medications (AEDs and rescue medications), medical monitoring devices, rideshare and transportation costs when driving is prohibited, home modifications for seizure safety (padding, pool safety, stair gates), and employment-related expenses (job coaching, work-from-home equipment).

Recommended structure for families with drug-resistant epilepsy: the ABLE account handles routine monthly costs — AED co-pays, transportation, medical visits. The SNT holds the long-term corpus and handles surgical episodes, device replacements, and extraordinary medical costs. For individuals whose epilepsy is severe enough to preclude independent financial management, an authorized individual (typically a parent or sibling) directs spending from both accounts.

Special Needs Trust planning for epilepsy families

A third-party Special Needs Trust is appropriate for any family member with epilepsy who receives SSI or Medicaid and may inherit assets from a parent's estate, receive a life insurance payout, or receive gifts from grandparents and extended family. The mechanics are identical to SNT planning for any disability — the trust receives assets, not the beneficiary directly, and the trustee makes distributions for the beneficiary's supplemental needs. See the first-party vs. third-party SNT guide for the structural details.

Epilepsy-specific SNT distribution language should explicitly authorize:

• Antiseizure medications and related pharmaceutical costs not covered by Medicaid or insurance
• Transportation costs for medical appointments and daily needs when the beneficiary cannot drive
• Seizure monitoring devices (wearable EEG devices, seizure alert devices, bed-pad monitors)
• Seizure rescue medications (intranasal midazolam, rectal diazepam) and related training costs for caregivers
• Epilepsy surgery evaluation costs (pre-surgical workup at tertiary centers, travel for centers of excellence)
• Device surgery and battery replacement costs for VNS, RNS, or DBS systems
• Home modification costs for seizure safety (bathroom padding, pool fencing, stair safety)
• Emergency responder identification (medical alert jewelry, digital health ID)

For individuals with drug-resistant epilepsy who cannot drive, the transportation cost category alone may require $100,000–$200,000 in SNT corpus over a 40–50 year planning horizon (present-value estimate at 3% discount rate). A specialist advisor can model this correctly; a generalist will often undercount it.

The three-professional team

1. Estate attorney specializing in special needs. Drafts the third-party SNT with distribution language tailored to epilepsy-specific expenses; amends parental wills; audits all beneficiary designations on IRAs, 401(k)s, and life insurance. For a family with a child who has severe epilepsy and intellectual disability, this is identical in scope to any developmental disability SNT engagement.
2. Fee-only financial advisor specializing in special needs. Sizes the SNT funding target for the specific epilepsy severity profile, models transportation costs over the planning horizon, structures life insurance to fund the SNT (survivorship or single-life depending on family structure), coordinates ABLE and SNT contributions, and accounts for AED cost scenarios across the medication lifecycle.
3. Benefits counselor or certified work incentives counselor (CWIC). For individuals with epilepsy who work or are exploring employment, a CWIC models the exact SSI earned income calculation, identifies impairment-related work expenses (IRWE) that may include assistive devices and adaptive transportation, confirms Section 1619(b) Medicaid protection eligibility, and helps structure ABLE-to-Work contributions. CWICs are available through state vocational rehabilitation agencies at no cost to the beneficiary.

What to do first

1. Assess SSI eligibility accurately. Many families of people with drug-resistant epilepsy either don't apply for SSI (thinking they won't qualify) or apply without understanding the Listing 11.02 criteria, making avoidable documentation errors. Seizure frequency must be documented with physician records covering the qualifying consecutive-month period. A benefits counselor or disability attorney can identify whether Listing 11.02A–D is met or whether an RFC-based claim is the right path.
2. Audit all beneficiary designations. Every IRA, 401(k), and life insurance policy owned by a parent or grandparent should name the SNT, not the family member with epilepsy directly. A direct inheritance above $2,000 in countable assets destroys SSI and Medicaid eligibility. This is the single most common planning error for epilepsy families with a mixed-severity picture — parents who don't think of their child as "disabled" because seizures are partially controlled, until a drug change disrupts control and SSI suddenly matters.
3. Establish a third-party SNT. The trust must exist before any asset transfer. Fund it with $1, then layer in life insurance as the primary funding vehicle over time. The cost of establishing an SNT ($1,500–$5,000 in attorney fees) is negligible relative to the Medicaid benefit value it protects.
4. Open an ABLE account. Begin making contributions for AED co-pays, transportation, medical appointments, and seizure safety equipment. The first $100,000 doesn't count toward SSI's $2,000 resource limit. A parent can open the ABLE account and serve as authorized individual when the beneficiary is a minor or cannot self-direct the account.
5. Enroll on HCBS waiver waitlist if intellectual disability is present. If your family member has epilepsy with intellectual disability (as in Dravet, LGS, or other severe childhood epilepsies), enroll on your state's DD waiver waitlist immediately. There is no minimum age requirement and no obligation to accept services when offered.
6. Price the transportation gap explicitly. If your family member cannot drive and relies on rideshare, paratransit, or family transportation, calculate the annual cost and include it in the SNT funding target. It's frequently the largest private-pay expense category over a multi-decade planning horizon — and the one most commonly omitted from generic SNT sizing conversations.

Sources

1. CDC — Epilepsy Data and Statistics. Approximately 3.0 million U.S. adults have active epilepsy (CDC National Health Interview Survey, 2021–2022). Annual health care spending for epilepsy and seizures was $24.5 billion in 2019.
2. Epilepsy Foundation — Drug-Resistant Epilepsy. Approximately 30% of people with epilepsy do not achieve seizure control with two adequate antiseizure medication trials; these individuals meet the ILAE definition of drug-resistant epilepsy (DRE).
3. Epilepsy Foundation — Driving Laws by State. Seizure-free intervals required for driving range from 3 to 18 months across states; 6 months is most common for adults. Five states plus the District of Columbia require 12 months. Commercial driver's license (CDL) holders must meet separate, stricter federal requirements.
4. SSA Blue Book — 11.00 Neurological Disorders (Adult). Listing 11.02 criteria for epilepsy: four pathways based on seizure type, frequency, and associated functional limitations. The qualifying period cannot begin earlier than one month after treatment was initiated.
5. Medical News Today — Epidiolex Cost 2026. Epidiolex (cannabidiol) annual cost estimated at approximately $12,600–$45,700 depending on patient age and weight-based dosing; $32,500/year was the original list price at 2018 launch. Out-of-pocket cost typically $0 with insurance and manufacturer patient assistance; without coverage, costs are prohibitive.
6. Epilepsy Foundation — Resective Surgery for Epilepsy. Temporal lobectomy achieves seizure freedom in approximately 60–70% of carefully selected candidates with temporal lobe epilepsy. Pre-surgical workup includes multiple evaluation steps (neuroimaging, EEG monitoring, neuropsychological testing) that may involve separate hospitalizations.
7. LivaNova — VNS Therapy CMS Reimbursement Increase (2026). Effective January 1, 2026, CMS increased hospital outpatient reimbursement for VNS Therapy new patient implants by approximately 48% versus 2025 rates and end-of-service procedures by approximately 47%. Total implantation costs including device, surgery, and facility fees typically run $35,000–$60,000+.

SSI and benefit rules verified against 2026 SSA standards. SSI FBR $994/month (2026). ABLE age limit expanded to 46 effective January 2026 (ABLE Age Adjustment Act). ABLE contribution limit $20,000/year; ABLE-to-Work additional $15,650/year; SEIE $9,730/year (2026). SSA Listing 11.02 criteria are current as of the SSA Blue Book neurological listings. State driving laws vary and are subject to change; verify current state requirements with your state DMV or neurologist. AED and device cost estimates reflect 2025–2026 market conditions; individual costs vary by insurance coverage, formulary, and geographic location.